Enigma Biomedical Group and Yale Sign Memorandum of Understanding to License Novel Investigational Synaptic Density Imaging Biomarker Technology

TORONTO--(BUSINESS WIRE)-- Enigma Biomedical Group (EBG) today announced execution of a Memorandum of Understanding to license Yale University’s Synaptic Density Imaging (SDI) biomarker technology platform. With this license, EBG will be responsible for the global development and commercialization of Yale’s early stage investigational imaging agents using Positron Emission Tomography (PET) to assess neurodegeneration. SDI promises to provide an important new tool in understanding neurodegenerative diseases such as Alzheimer’s and other dementias.

As part of the agreement, EBG will be responsible for the clinical development and commercialization of these SDI agents in return for payment of license fees, milestone payments and royalties on worldwide sales of any future products. EBG, and its partner, Cerveau Technologies, Inc., will work with their collective pharmaceutical industry partners to apply this technology together with the development of therapies expected to impact the progression of neurodegenerative diseases.

Lee Ann Gibbs, President of Enigma Biomedical Group said, “This is an important step in accelerating critical biomarker research projects globally. Licensing the Yale technology platform allows Enigma, and its partner, Cerveau Technologies Inc., to continue to execute the collective strategy of providing biomarkers to industry and academia to accelerate research in the field of neurodegenerative diseases.”

“Synapses are essential for neural transmission and cognitive function, and in the past few years the Yale PET Center has focused on the development of radiopharmaceuticals for use in SDI. We are pleased to collaborate with Enigma Biomedical Group to further develop and validate this technology in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, as well as other neurologic disorders.” said Dr. Yiyun Henry Huang, Professor, Department of Radiology and Biomedical Imaging, and Director of Chemistry and Co-Director, Yale PET Center, the lead inventor of the technology, “SDI holds great promise for the early diagnosis of neurodegenerative diseases, and for monitoring the efficacy of disease-modifying therapies that repair and restore synaptic function. While we expect the application of SDI to accelerate the development of therapeutics for Alzheimer’s disease and other neurodegenerative disorders, this technology may also provide a unique and valuable tool to investigate brain development and other diseases associated with altered synaptic function such as autism, schizophrenia, and addictions.”

“At Enigma, we are focused on providing information and technologies to researchers and clinicians to enable the improvement of brain health,” said Rick Hiatt, Chief Executive Officer of Enigma Biomedical Group and President and CEO of Cerveau Technologies, Inc. “We are thrilled by the opportunity to work with Yale to foster development of this exciting technology. Consistent with our vision, we will make these novel imaging agents available to our pharmaceutical industry and academic partners, providing access to the broader scientific community.”

About Enigma Biomedical Group

Toronto-based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine. EBG offers a suite of services to the pharmaceutical industry and clinical research community to accelerate drug development and global access. EBG partners with academic institutions and universities to foster and broaden access to novel research.

About Cerveau Technologies, Inc.

Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.



Enigma Biomedical Group
Lee Anne Gibbs


Source: Enigma Biomedical Group

Back to news